Company profile: Biosplice
1.1 - Company Overview
Company description
- Provider of therapeutic solutions and clinical trials for tissue-level regeneration, developing therapies that modulate alternative splicing via CLK/DYRK kinase inhibition to treat diseases like osteoarthritis and cancer. Offerings include Lorecivivint, an injectable small molecule for knee osteoarthritis to reduce pain, improve function, and protect cartilage, with trials evaluating safety, efficacy, and dosing.
Products and services
- Clinical Trials: Clinical-stage research studies that test safety, efficacy, and optimal dosing of investigational treatments, including the evaluation of Lorecivivint for knee osteoarthritis
- Lorecivivint: Kinase-directed, injectable small-molecule inhibitor of CLK/DYRK family kinases formulated for knee osteoarthritis, reducing pain, improving function, and protecting cartilage
- Therapeutic Modulation of Alternative Splicing: Mechanism-driven development of therapies that target CLK/DYRK family kinases to modulate alternative splicing for diseases such as osteoarthritis and cancer
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Biosplice
Cyclo Therapeutics
HQ: United States
Website
- Description: Provider of cyclodextrin-based therapeutics, including Trappsol® Cyclo™, a proprietary hydroxypropyl beta cyclodextrin formulation in clinical trials for Niemann-Pick Disease Type C1 and in a Phase 2b trial for early Alzheimer’s disease, leveraging data from an Expanded Access program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cyclo Therapeutics company profile →
Q BioMed
HQ: United States
Website
- Description: Provider of radiopharmaceutical and therapeutic candidates, including Strontium-89 Chloride Injection for relief of bone pain from skeletal metastases; Uttroside-B, a chemotherapeutic agent under development for liver cancer; QBM-001, a preclinical candidate targeting pediatric minimally verbal autism spectrum disorder; and MAN-01, a preclinical topical eyedrop for glaucoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Q BioMed company profile →
Prismic Pharmaceuticals
HQ: United States
Website
- Description: Provider of novel prescription medical drugs for inflammatory diseases and prescription medical foods for the clinical dietary management of metabolic processes associated with disorders common in the aging 'baby boomer' population, including central nervous system disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Prismic Pharmaceuticals company profile →
UPSA
HQ: France
Website
- Description: Provider of pharmaceuticals, food supplements, and medical devices for the fight against pain and self-medication, serving patients from infants to seniors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full UPSA company profile →
Roquefort Therapeutics
HQ: United Kingdom
Website
- Description: Provider of pre-clinical anti-cancer therapeutics, including Midkine-targeting antibodies; antisense oligonucleotides to reduce Midkine in cancer cells; gene-editing RNA and mRNA therapies for solid tumors; STAT-6 siRNA therapeutics; and MK cell therapy with direct and NK cell-mediated action, advancing candidates toward clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Roquefort Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Biosplice
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Biosplice
2.2 - Growth funds investing in similar companies to Biosplice
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Biosplice
4.2 - Public trading comparable groups for Biosplice
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →